Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: Prognostic factors and generalizability of a multicenter trial to clinical practice

Journal of Urology

Volumn 163, Issue 5, 2000, Pages 1481-1485

  Dowling, Anthony J ^a,b,c   Czaykowski, Piotr M ^a,b,c   Krahn, Murray D ^a,b,c   Moore, Malcolm J ^a,b,c   Tannock, Ian F ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c St Vincenta's Hospital   (Australia)

Author keywords

Drug therapy; Mitoxantrone; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

ALKALINE PHOSPHATASE; HEMOGLOBIN; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANADA; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034007184     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67647-1     Document Type: Article

References (13)

1. Landis, S. H., Murray, T., Bolden, S., et al: Cancer statistics, 1998. CA Cancer J Clin, 48: 6, 1998
2. Tannock, I. F., Osoba, D., Stockier, M. R. et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol, 14: 1756, 1996
3. Osoba, D., Tannock, I. F., Ernst, D. S., et al: Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol, 17: 1654, 1999
4. Kantoff, P. W., Halabi, S., Conaway, M. et al: Hydrocortisone with or without mitoxantrone in patients with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol, 17: 2506, 1999
5. Antman, K., Amato, D., Wood, W., et al: Selection bias in clinical trials. J Clin Oncol, 3: 1142, 1985
6. Davis, S., Wright, P. W., Schulman, S. F., et al: Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with non-participants in such trials. Cancer, 56: 1710, 1985
7. Karjalainen, S. and Palva, I.: Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. Br Med J, 299: 1069, 1989
8. Altman, D. G.: Practical Statistics for Medical Research. New York: Chapman and Hall, 1991
9. Parmar, M. K. B. and Machin, D.: Survival Analysis. A Practical Approach. Chichester: John Wiley & Sons, pp. 65-96, 1995
10. Kelly, W. K., Scher, H. I., Mazumdar, M., et al: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol, 11: 607, 1993
11. Smith, D. C., Dunn, R. L., Strawderman, M. S., et al: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol, 16: 1835, 1998
12. Scher, H. I., Kelly, W. M., Zhang, Z. F. et al: Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst, 91: 244, 1999
13. Hussain, M., Wolf, M., Marshall, E. et al: Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol, 12: 1868, 1994